Canakinumab

Drug Profile

Canakinumab

Alternative Names: ACZ-885; Anti-IL-1 beta monoclonal antibody; Anti-interleukin-1 beta monoclonal antibody; Antibody A; Ilaris

Latest Information Update: 25 Jun 2017

Price : $50

At a glance

  • Originator Novartis
  • Developer Novartis; Triemli hospital; University Hospital Tubingen; University Hospital Zurich
  • Class Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Juvenile rheumatoid arthritis; Inflammation; Familial Mediterranean fever; Familial autosomal dominant periodic fever
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Adult-onset Still's disease; Cryopyrin-associated periodic syndromes; Familial autosomal dominant periodic fever; Familial Mediterranean fever; Gouty arthritis; Juvenile rheumatoid arthritis; Peroxisomal disorders
  • Phase III Behcet's syndrome; Cardiovascular disorders
  • Phase II Abdominal aortic aneurysm; Atherosclerosis; Osteoarthritis; Peripheral arterial occlusive disorders; Pulmonary sarcoidosis
  • Phase I Diabetic retinopathy
  • No development reported Chronic obstructive pulmonary disease
  • Discontinued Asthma; Polymyalgia rheumatica; Rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 22 Jun 2017 Efficacy data from the phase III CANTOS trial in Cardiovascular disorders (Prevention) released by Novartis
  • 04 Apr 2017 Novartis intends to submit NDA to the US FDA for Cardiovascular disorders (Prevention) in 2017
  • 16 Feb 2017 Novartis withdraws a phase II trial in Mucocutaneous Lymph Node Syndrome (In neonates, In infants, In children) prior to enrolment in Belgium, Germany, Italy (NCT02980263) (EudraCT2015-003763-11)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top